Month: May 2023

Image: GreenLight Biosciences Image: GreenLight BiosciencesBOSTON, May 11, 2023 (GLOBE NEWSWIRE) — GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023. “GreenLight is sharply focused on its mission, leveraging scientific expertise, global partnerships, and the power of our platform to progress innovative RNA-based products for plant health and human health,” said Andrey Zarur, CEO of GreenLight. “Following regulatory submission of our Varroa mite honeybee solution in the first quarter, we now have two products under EPA review. Pending regulatory approval anticipated this year, we are actively preparing for commercial...

Strong performance driving revenue and Adjusted EBITDA growth MISSISSAUGA, Ontario, May 11, 2023 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q1 2023 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 13.5% interest in Kruger Products. Kruger Products Q1 2023 Business and Financial HighlightsRevenue was $451.0 million in Q1 2023 compared to $398.7 million in Q1 2022, an increase of $52.3 million or 13.1%. Adjusted EBITDA1...

UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023. HighlightsFirst quarter 2023 revenue totaled $27.5 million, representing year over year growth of 21% on a reported basis and 25% on a constant currency adjusted like-for-like basis Total Explore customer installations reached 63, with 11 installations during the first quarter Total Signature Q100 placements reached 117, with 26 placements during the first quarter Explore revenue of $16.9 million accounted for 61% of total first quarter revenue, with Explore Kit revenue totaling $9.4 million, or 56% of total Explore revenues First quarter kits revenue and analysis services revenue represented 49% and 38% of total revenue, respectively First...

 LONDON, May 11, 2023 (GLOBE NEWSWIRE) —Highlights:COMP360 Phase 3 pivotal program underway, patients have been treated in both trials CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association Cash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarter Conference call today at 8:00am ET (1:00pm UK)COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, “Our phase 3 pivotal trials in treatment-resistant depression are now underway...

Kojamo plc Stock Exchange Release, 11 May 2023 at 2.00 p.m. EEST Kojamo plc’s Interim Report 1 January – 31 March 2023 Growth in total revenue and net rental income continued, the number of rental apartments 39,550 This is a summary of the January–March Interim Report, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in this Interim Report have not been audited. Summary of January–March 2023Total revenue increased by 8.8 per cent to EUR 108.2 (99.5) million Net rental income increased by 4.3 per cent to EUR 59.5 (57.0) million. Net rental income was 55.0 (57.3) per cent of total revenue Profit before taxes was EUR 24.0 (62.9) million....

– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiated in the second half of 2023 – – Phase 1 randomized, double-blind, placebo-controlled FREEDOM-DM1 study expected to be initiated in the first half of 2023 – – Ended first quarter 2023 with cash, cash equivalents, and investments of $165.4 million; Cash runway expected into 2025 – BOSTON, May 11, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first...

Reports 12% increase in gross profit for the first quarter of 2023 ROSELAND, N.J., May 11, 2023 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the first quarter ended March 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid revenues of $2.6 million for the first quarter of 2023. Most notably, domestic dental sales increased 47%, due in part to the early success of our new online store for selling and shipping the STA Single Tooth Anesthesia System® (STA) and handpieces directly to dental offices and dental groups within the U.S. This strategy has provided us a closer and more direct relationship with...

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2023, and provided recent corporate updates. “Galera has made tremendous progress since the start...

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments. First Quarter 2023 Highlights and New Developments Clinical UpdatesAt a recent R&D webcast on April 20, 2023, the Company:Reviewed its ongoing clinical programs in AD and PD.Discussed preliminary plans to develop buntanetap with the FDA for all stages of diseases, both short- and long-term.Provided updates to its then current enrollment levels for each trial:AD Phase 2/3 study: 27 sites had been activated and 38 patients had been screened as of April 20; 13 patients had been randomized to receive either one of three doses...

Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Following the dosing and completion of our first patient in the first cohort of our INDP-D101 trial of Decoy20 for the treatment of solid tumors, we continue the screening and enrollment process to complete our first cohort,” said Jeffrey Meckler, chief executive officer of Indaptus. “In the interim, we have presented significant data at the American Association for Cancer Research scientific conference and received additional recognition within the scientific community. We have...